发明名称 |
Suppression of neuroendocrine diseases |
摘要 |
The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods. |
申请公布号 |
US8796216(B2) |
申请公布日期 |
2014.08.05 |
申请号 |
US201012969810 |
申请日期 |
2010.12.16 |
申请人 |
Syntaxin Limited |
发明人 |
Johnstone Stephen;Marks Philip;Foster Keith |
分类号 |
A61K38/16;C07K14/33;C12P21/00 |
主分类号 |
A61K38/16 |
代理机构 |
Morris, Manning & Martin, LLP |
代理人 |
Morris, Manning & Martin, LLP ;Raimund Christopher W. |
主权项 |
1. A polypeptide comprising the amino acid sequence of SEQ ID NOs: 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 or 111. |
地址 |
Abingdon, Oxfordshire GB |